Supplementary Data 1 from Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER<sup>+</sup> Breast Cancer Models
Sheryl M. Gough(Arvinas (United States)), John J. Flanagan(Arvinas (United States)), Jessica L.F. Teh(Arvinas (United States)), Monica Andreoli(Arvinas (United States)), Emma Rousseau(Arvinas (United States)), Melissa Pannone(Arvinas (United States)), Mark Bookbinder(Arvinas (United States)), Ryan R. Willard(Arvinas (United States)), Kim Davenport(Arvinas (United States)), Elizabeth Bortolon(Arvinas (United States)), Gregory Cadelina(Arvinas (United States)), Debbie Gordon(Arvinas (United States)), Jennifer Pizzano(Arvinas (United States)), Jennifer Macaluso(Arvinas (United States)), Leofal Soto(Arvinas (United States)), John Corradi(Arvinas (United States)), Katherine M. Digianantonio(Arvinas (United States)), Ieva Drulyte(Thermo Fisher Scientific (Netherlands)), Alicia Morgan(Arvinas (United States)), Connor Quinn(Arvinas (United States)), Miklós Békés(Arvinas (United States)), Caterina Ferraro(Arvinas (United States)), Xin Chen(Arvinas (United States)), Gan Wang(Arvinas (United States)), Hanqing Dong(Arvinas (United States)), Jing Wang(Arvinas (United States)), David R. Langley(Arvinas (United States)), John Houston(Arvinas (United States)), Richard Gedrich(Arvinas (United States)), I Taylor(Arvinas (United States))
Cited by 0Open Access
Abstract
<p>Extended Methods</p>
Related Papers
No related papers found
Powered by citation graph analysis